Adaptive Biobehavioral Control (ABC) in a Closed-Loop System: A Randomized Crossover Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 73
- 试验地点
- 2
- 主要终点
- CGM-measured percent time in range 70-180 mg/dL
研究概览
简要总结
This study is intended to test a Web-based Information Tool (WIT) software providing additional information regarding time in range, GMI, hypo- and hyperglycemia risks, variability tracker, daily glycemic profiles, and potential changes of insulin pump parameters, to users of a commercially available Closed-Loop Control (CLC) System (Control-IQ Technology).
详细描述
This is a randomized two-arm crossover group trial in which both groups will use the CLC (Control-IQ) plus WIT. The difference between the two groups will be the order of the interventions. Each group will undergo screening and collection of baseline data from their personal AID system (Control-IQ) followed by randomization 1:1 into two groups. Both groups will have the same three interventions but will progress in the study in a different order allowing for crossover comparisons. The three interventions are:
- Use of personal CLC system for 2 weeks
- Use of personal CLC system and adding a behavioral adaptation module (BAM) for 4 weeks
- Use of personal CLC system and adding the ABC which includes: BAM and PAM (which includes ATM and WST described below) for 16 weeks.
The BAM will consist of modules in which information only is given to participants (e.g. time in range, Glucose Management Indicator (GMI), hyper-and hypoglycemic risks, daily glycemic profiles, and variability tracker). The PAM includes auto suggestions for titration of insulin pump parameters every two weeks (ATM) and is aided by a web simulation tool (WST) which can replay 'what if' scenarios for the participant based on various combinations of insulin pump parameter changes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18.0 and ≤70 years old at time of consent
- •Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year
- •Currently using an insulin pump for at least six months
- •Currently using insulin for at least six months
- •Currently using the t:slim X2 insulin pump for at least two months
- •Currently using or anticipated to be using the t:slim X2 insulin pump with Control-IQ technology at randomization (Visit 3).
- •Using or willing to use insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections
- •Access to internet and willingness to upload data during the study as needed
- •Willing to use an app on a smart phone during the study.
- •For females, not currently known to be pregnant or breastfeeding
- •If female, sexually active, and of childbearing potential, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
- •Willingness to use only insulin analogs approved for use in the t:slim X2 pump such as lispro (Humalog) or as part (Novolog) and not use ultra-rapid acting insulin analogs (e.g., FiAsp) during the study
- •Total daily insulin dose (TDD) at least 10 units per day
- •Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial (including metformin (biguanides), GLP-1 receptor agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)
- •An understanding and willingness to follow the protocol and signed informed consent
排除标准
- •Concurrent use of any non-insulin glucose-lowering agent other than metformin or GLP-1 receptor agonists following screening (including pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)
- •A condition, which in the opinion of the investigator or designee, would put the participant at risk or interfere with the completion of the protocol.
- •History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment
- •Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
- •Currently being treated for a seizure disorder
- •Hemophilia or any other bleeding disorder
- •Planned surgery during study duration
- •Participation in another pharmaceutical or device trial at the time of enrollment or during the study
- •Having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (e.g., study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial.
研究组 & 干预措施
CLC, then CLC+BAM, then CLC+ABC
Participants will be using closed loop control (CLC) for 2 weeks. Participants will then use closed loop control (CLC) with behavioral adaption module (BAM) for 4 weeks, followed by closed loop control (CLC) adaptive biobehavioral control (ABC) for 16 weeks.
干预措施: CLC + BAM (Device)
CLC, then CLC+BAM, then CLC+ABC
Participants will be using closed loop control (CLC) for 2 weeks. Participants will then use closed loop control (CLC) with behavioral adaption module (BAM) for 4 weeks, followed by closed loop control (CLC) adaptive biobehavioral control (ABC) for 16 weeks.
干预措施: CLC + ABC (Device)
CLC+ABC, then CLC+BAM, then CLC
Participants will be using closed loop control (CLC) with adaptive biobehavioral control (ABC) for 16 weeks. Participants will then use closed loop control (CLC) with behavioral adaptation module (BAM) for 4 weeks, followed by closed loop control (CLC) for 2 weeks.
干预措施: CLC + BAM (Device)
CLC+ABC, then CLC+BAM, then CLC
Participants will be using closed loop control (CLC) with adaptive biobehavioral control (ABC) for 16 weeks. Participants will then use closed loop control (CLC) with behavioral adaptation module (BAM) for 4 weeks, followed by closed loop control (CLC) for 2 weeks.
干预措施: CLC + ABC (Device)
结局指标
主要结局
CGM-measured percent time in range 70-180 mg/dL
时间窗: 4 weeks
The primary outcome for this study is CGM-measured percent time in range 70-180 mg/dL over the last 4-week periods on CLC+ABC versus 2 weeks of the current CLC system. The intervention will be considered effective if the CLC+ABC is superior to the CLC alone in a crossover design using a statistical significance of α=0.05. To preserve the overall type 1 error for selected key secondary endpoints, a hierarchical testing procedure will be used. If the primary analysis for time in range described above results in a statistically significant result (p \< 0.05), then testing (similar to the model for the primary outcome) will proceed to the next key secondary outcome metric in the following order entered.
CGM-measured Percent Time in Range 70-180 mg/dL
时间窗: 2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC
The primary outcome for this study is CGM-measured percent time in range 70-180 mg/dL over the last 4-week periods on CLC+ABC versus 2 weeks of the current CLC system.
次要结局
- CGM-measured percent above 180 mg/dL during the day(4 weeks)
- CGM-measured mean glucose(4 weeks)
- CGM-measured coefficient of variation during the day(4 weeks)
- CGM-measured percent below 70 mg/dL during the day(4 weeks)
- CGM-measured Percent Above 180 mg/dL During the Day(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- CGM-measured Percent Below 70 mg/dL During the Day(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- CGM-measured Mean Glucose(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- CGM-measured Coefficient of Variation During the Day(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- Time in Range (70-140 mg/dL)(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- TIR <60 mg/dL(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- Low Blood Glucose Index (LBGI)(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- High Blood Glucose Index (HBGI)(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- TIR >250 mg/dL(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- TIR >300 mg/dL(2 weeks of CLC, 4 weeks of CLC+BAM, last 4 weeks of CLC+ABC)
- HbA1c (%) at End of Study(Labs taken at the completion of study, approximately 6 months after enrollment; hence, results are stratified only by arm and not by intervention.)
- Technology Expectations Survey(Participant baseline)
- Clarke's Hypoglycemia Awareness Scale(22 weeks)
- Technology Experience Survey(At participant completion, approximately 6 months)
- High Blood Glucose Levels Survey(22 weeks)
- Hypoglycemia Fear Survey(22 weeks)
- Diabetes Distress Scale(22 weeks)
研究者
Sue Brown
Study Physician
University of Virginia